Titles and Legends to Supplemental Figures
Supplemental Figure 1 Cytotoxic effect of NSC697923 on NB cells. (a) NGP, NB-19
and CHLA-255 cells were treated with the indicated concentrations of NSC697923
for 24 hrs and then cell morphology was captured using optical microscope. (b) NGP,
NB-19 and CHLA-255 cells were first incubated with the indicated concentrations of
NSC697923 for 24 hrs, stained by propidium iodide (PI) without fixing and then
analyzed by flow cytometry. PI positive cells were shown by percentage. Data from
(a) and (b) are representative of three independent experiments.
Supplemental Figure 2 Cytotoxic effect of NSC697923 on the chemoresistant NB cell
line LA-N-6. (a) LA-N-6 cells were treated with indicated concentrations of
NSC697923, Dox or VP16 for 24 hrs and then cell morphology was captured using
optical microscope. (b) LA-N-6 cells were incubated with indicated concentrations of
NSC697923 and grown in RPMI 1640 media for 2 weeks. The colonies produced
were then fixed, stained with crystal violet dye, and photographed. Data from (a) and
(b) are representative of three independent experiments.
Supplemental References
1. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified
DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell
lines and a neuroblastoma tumour. Nature 1983;305:245-8.
2. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, et al. Transposition and
amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-67.
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human
neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res
1998;58:5396-405.
4. Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, De Paepe A, et al. Comparative
genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and
further molecular genetic characterization of neuroblastoma cell lines. Cancer Genet
Cytogenet 1997;97:135-42.
5. Sadée W, Yu VC, Richards ML, Preis PN, Schwab MR, Brodsky FM, et al. Expression of
neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma
cell line. Cancer Res 1987;47:5207-12.
6. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human
neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992;7:127-33.
7. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and
function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in
MYCN-amplified cells. Am J Pathol 2001;158:2067-77.
8. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC
(Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:3558.
9. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. COSMIC 2005. Br
J Cancer 2006;94:318-22.
10. Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional
characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma
cell line. Biochem Biophys Res Commun 2007;354:892-8.
11. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53
function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res
2001;61:6185-93.
12. Goto H, Yang B, Petersen D, Pepper KA, Alfaro PA, Kohn DB, et al. Transduction of
green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic
drugs in neuroblastoma cell lines. Mol Cancer Ther 2003,2:911-7.